Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Biogen
Biogen
FDA Approves Biogen, Sage’s Zurzuvae as First Pill for Postpartum Depression
BioSpace
Sun, 08/6/23 - 09:39 pm
Biogen
SAGE Therapeutics
FDA
Zurzuvae
postpartum depression
major depressive disorder
zuranolone
Biogen looks at selling biosims unit to longtime ally Samsung Bioepis: reports
Fierce Pharma
Thu, 08/3/23 - 09:59 am
Biogen
biosimilars
M&A
Samsung Bioepis
The real costs of the new Alzheimer’s drug, most of which will fall to taxpayers
Medical Marketing and Media
Wed, 08/2/23 - 10:43 pm
Eisai
Biogen
Leqembi
Alzheimer's disease
Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know.
Motley Fool
Tue, 08/1/23 - 11:55 am
Biogen
Reata Pharmaceuticals
M&A
After quitting FDA adcomm in protest of Aduhelm decision, Harvard's Aaron Kesselheim finds agency has an approval bias
Fierce Pharma
Mon, 07/31/23 - 10:07 am
FDA
Biogen
Aduhelm
Alzheimer's disease
advisory committees
drug approvals
FDA Action Alert: Mesoblast, Sage/Biogen and Galera
BioSpace
Mon, 07/31/23 - 10:05 am
FDA
graft vs host disease
head and neck cancer
postpartum depression
major depressive disorder
Mesoblast
remestemcel-L
Biogen
SAGE Therapeutics
zuranolone
Galera Therapeutics
avasopasem manganese
Go or no go? Biogen and Astellas head towards key PDUFAs
EP Vantage
Sat, 07/29/23 - 10:45 pm
FDA
Astellas
Zimura
Biogen
SAGE Therapeutics
zuranolone
major depressive disorder
postpartum depression
geographic atrophy
Biogen to acquire rare disease drugmaker Reata for $7.3B
BioPharma Dive
Fri, 07/28/23 - 11:50 am
Biogen
Reata Pharmaceuticals
M&A
Friedreich's Ataxia
Sage Stock Drops Despite Promising Phase III Depression Data
BioSpace
Thu, 07/27/23 - 11:30 am
SAGE Therapeutics
zuranolone
Biogen
depression
I Was Concerned About Biogen Until I Heard These 11 Words From Its CEO
Motley Fool
Thu, 07/27/23 - 10:17 am
Biogen
Alzheimer's disease
Pharma CEOs
Chris Viehbacher
Biogen to eliminate 1,000 jobs in further cost cuts
BioPharma Dive
Tue, 07/25/23 - 11:58 am
Biogen
layoffs
R&D
After winning full FDA nod for Leqembi, Eisai touts 'promising' study on subcutaneous version
Fierce Pharma
Thu, 07/20/23 - 10:09 am
Eisai
Biogen
Leqembi
FDA
Alzheimer's disease
subcutaneous drug delivery
Lilly’s donanemab flaunts strong clinical profile, ready to compete with Leqembi
Clinical Trials Arena
Wed, 07/19/23 - 10:27 am
Eli Lilly
donanemab
Eisai
Biogen
Leqembi
Alzheimer's disease
Medicare’s Proposed Coverage for Alzheimer’s Scan Could Be Boon for Eisai/Biogen
BioSpace
Tue, 07/18/23 - 11:36 am
CMS
Alzheimer's disease
Eisai
Biogen
PET scans
Why new Alzheimer’s drugs are in for a tepid launch
Medical Marketing and Media
Sun, 07/16/23 - 03:11 pm
Alzheimer's disease
drug launches
Biogen
Eisai
Leqembi
Why Isn't Biogen Stock Soaring After This Major FDA Approval?
Motley Fool
Thu, 07/13/23 - 10:16 am
Biogen
Eisai
Leqembi
Alzheimer's disease
How will the price of Eisai and Biogen's Leqembi impact Medicare? Sen. Sanders wants to know
Fierce Pharma
Wed, 07/12/23 - 11:03 pm
Eisai
Biogen
Leqembi
drug pricing
Medicare
Alzheimer's disease
Following in Biogen's wake, BrainStorm analyzes effect of ALS cell therapy on biomarker
Fierce Biotech
Fri, 07/7/23 - 08:40 am
BrainStorm Cell Therapeutics
ALS
cell therapy
Biogen
NurOwn
Leqembi Wins Full FDA Approval as First Anti-Amyloid Antibody for Alzheimer’s
BioSpace
Thu, 07/6/23 - 10:08 pm
Biogen
Eisai
Leqembi
FDA
Alzheimer's disease
9 Highly Anticipated FDA Decisions in Second Half of 2023
BioSpace
Fri, 06/30/23 - 11:52 am
FDA
Eisai
Biogen
Leqembi
Alzheimer's disease
SAGE Therapeutics
zuranolone
postpartum depression
major depressive disorder
Roche
Tecentriq
non-small cell lung cancer
CRISPR Therapeutics
Bluebird Bio
lovo-cel
exa-cel
BrainStorm Cell Therapeutics
NurOwn
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »